Published in Blood Weekly, September 28th, 1998
The possibility of ex vivo expansion of primitive hematopoietic cells is of considerable interest for both gene therapy and transplantation applications. Unfortunately, early preclinical and clinical studies of transduced hematopoietic progenitor cells have resulted in levels of engraftment of the genetically altered cells that were too low to be of clinical benefit (C.E. Dunbar et al., Curr Opin Hematol, 1996;3:430).
J.F. Tisdale and colleagues from the National Institutes of Health, Maryland, sought...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.